pharmaceuticals

Over the objections of drugmakers, the Trump administration is expected within weeks to finalize its plan that would allow states to import some…

The order, which would include Medicare parts B and D, replaces a previous order the president signed in July, but the move is unlikely to have any immediate practical impact.

In a business driven by profit, vaccines have a problem. They’re not very profitable — at least not without government subsidies. Pharma companies favor…

The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?

Thousands of lawsuits that ground to a halt because of COVID-19 are moving forward again as local, state and federal courts reopen around the U.S.

Lawsuits over the way drugmakers have marketed opioids are already putting a dent in companies' reputations. Litigation has forced the release of internal documents that are shifting the narrative.

Senators railed against pharmaceutical executives Tuesday for declining to testify before Congress about out-of-control drug prices, as lawmakers on both…

President Donald Trump’s new budget proposal flirts with combating high prescription drug prices, but industry watchers say the tweaks to Medicare and…

Alex Azar’s job hop from drug-maker Eli Lilly to the Trump administration reflects ever-deepening ties between the pharmaceutical industry and the federal…

A 25-year-old federal drug discount program has grown so big and controversial that it faces a fight for survival as federal officials and lawmakers…